2014年9月10日星期三

ABC294640 supplier|cas 915385-81-8 |DC Chemicals|Supplier|Price|Buy  

ABC294640 supplier|cas 915385-81-8 |DC Chemicals|Supplier|Price|Buy

DC Chemicals Supply: ABC294640 supplier,cas 915385-81-8, Cat No. DC5027, In stock

Contact: website: www.dcchemicals.com,
sales@dcchemicals.com,order@dcchemicals.com,info@dcchemicals.com,
Tel: +86-21-61454686;Fax:+86-21-61642799;

Product name: ABC294640, Synonym: ABC294640; ABC-294640; ABC 294640; 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide., Cat No. DC5027, Cas: 915385-81-8, Chemical Name:N/A, Molecular Formula: C23H25ClN2O, MW: 380.91

ABC294640,cas 915385-81-8, Purity: >98%. Best Price and quality in the market,DC Chemicals,Primary Manufacturer, confirmed by HNMR and HPLC. ABC294640 is an orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity. Upon administration, ABC294640 competitively binds to and inhibits SK2, thereby preventing the phosphorylation of the pro-apoptotic amino alcohol sphingosine to sphingosine 1-phosphate (S1P), the lipid mediator that is pro-survival and critical for immunomodulation. This may eventually lead to the induction of apoptosis and may result in an inhibition of cell proliferation in cancer cells overexpressing SK2. SK2 and its isoenzyme SK1 are overexpressed in numerous cancer cell types.

ABC294640 is an orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity. Upon administration, ABC294640 competitively binds to and inhibits SK2, thereby preventing the phosphorylation of the pro-apoptotic amino alcohol sphingosine to sphingosine 1-phosphate (S1P), the lipid mediator that is pro-survival and critical for immunomodulation. This may eventually lead to the induction of apoptosis and may result in an inhibition of cell proliferation in cancer cells overexpressing SK2. SK2 and its isoenzyme SK1 are overexpressed in numerous cancer cell types.

没有评论:

发表评论